Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
9.97
Nov 10 • 3:59 PM ET Dollar change-0.83 Percentage change(-7.69%)
Aftermarket Close
10.04
Aftermarket • 7:30 PM ET Dollar change+0.07 Percentage change(0.70%)
Index
RUT
Market Cap
1.71B
Enterprise Value
1.51B
Income
-121.08M
Sales
1.56M
Book/sh
1.43
Cash/sh
1.17
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
140
IPO
Jul 22, 2021
P/E
-
Forward P/E
-
PEG
-
P/S
1096.79
P/B
6.95
P/C
8.51
P/FCF
-
EV/EBITDA
-
EV/Sales
970.31
Quick Ratio
10.63
Current Ratio
10.63
Debt/Eq
0.02
LT Debt/Eq
0.01
Option/Short
Yes / Yes
EPS (ttm)
-0.80
EPS next Y
-0.74
EPS next Q
-0.19
EPS this Y
5.15%
EPS next Y
7.30%
EPS next 5Y
10.61%
EPS past 3/5Y
9.99% -9.45%
Sales past 3/5Y
-21.31% -10.14%
EPS Y/Y TTM
15.36%
Sales Y/Y TTM
-62.28%
EPS Q/Q
11.98%
Sales Q/Q
-46.37%
Insider Own
13.68%
Insider Trans
0.21%
Inst Own
84.26%
Inst Trans
18.66%
ROA
-50.57%
ROE
-57.72%
ROIC
-48.87%
Gross Margin
-610.70%
Oper. Margin
-8411.27%
Profit Margin
-7756.37%
SMA20
0.86%
SMA50
3.55%
SMA200
47.99%
Trades
Shs Outstand
171.56M
Shs Float
148.14M
52W High
12.54 -20.53%
52W Low
2.24 345.09%
Volatility
11.11% 10.24%
ATR (14)
1.05
RSI (14)
49.89
Beta
2.19
Rel Volume
1.10
Avg Volume
3.73M
Volume
4,101,938
Perf Week
-0.30%
Perf Month
3.10%
Perf Quarter
4.95%
Perf Half Y
86.18%
Perf YTD
185.67%
Perf Year
200.30%
Perf 3Y
685.04%
Perf 5Y
-22.65%
Perf 10Y
-
Prev Close
10.80
Price
9.97
Change %
-7.69%
Consensus
Strong Buy
Avg. Price Target
$14.82
Implied Upside
+48.6%
Analysts16incl. previous ratings
Rating Distribution12 Buy · 3 Hold · 1 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Oct 29, 2026Initiated
JEF logoJJefferies
Buy$14+40.4%
Jun 04, 2026Initiated
LLeerink Partners
Outperform$12+20.4%
May 28, 2026Initiated
BBTIG Research
Buy$9-9.7%
Jan 08, 2026Downgrade
MS logoMMorgan Stanley
Overweight → Equal-Weight$4.32-56.7%
Oct 02, 2025Initiated
JPM logoJJP Morgan
Overweight
Jul 03, 2025Resumed
MS logoMMorgan Stanley
Overweight$7-29.8%
Jan 22, 2025Initiated
NNeedham
Buy$9-9.7%
Oct 02, 2024Initiated
GGuggenheim
Buy$10+0.3%
Jul 03, 2024Initiated
MS logoMMorgan Stanley
Overweight$7-29.8%
Mar 14, 2024Initiated
BNS logoBScotiabank
Sector Outperform$13+30.4%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Szela Mary TDirectorJun 30 '26Buy11.5412,900148,86621,300Jul 06 04:06 PM
Pangalos Menelas NDirectorMay 13 '26Buy5.3637,453200,748232,308May 13 04:05 PM
Busch AndreasChief Innovation OfficerMar 12 '26Buy2.29100,000229,000421,446Mar 16 04:17 PM
Pangalos Menelas NDirectorFeb 27 '26Buy2.7475,095205,760189,055Mar 03 04:13 PM
McClain SeanChief Executive OfficerFeb 23 '26Option Exercise1.21396,399479,6438,730,966Feb 25 06:05 PM
McClain SeanChief Executive OfficerFeb 02 '26Sale2.9926,76180,0158,334,567Feb 04 04:52 PM
Jonasson ZachariahCFO / CBOFeb 02 '26Sale2.9917,49652,313383,538Feb 04 04:51 PM
VAN HOUTEN FRANSDirectorDec 05 '25Buy3.7240,000148,80063,320Dec 09 04:04 PM
Absci Corp. engages in drug discovery with generative design to create biologics for patients. Its platform combines AI models with a synthetic biology data engine, enabling the design of therapeutics that address challenging therapeutic targets. The firm has its own pipeline of AI designed therapeutics including ABS-201 and ABS-202. Absci Corp was founded by Sean McClain in 2011 and is headquartered in Vancouver, WA.
FounderMr. Sean McClain
Chief Business Officer & CFODr. Zachariah Jonasson Ph.D.
Senior VP & Chief Accounting OfficerMr. Todd Bedrick CPA
CVP of Finance & Head of Investor RelationsMr. Alexander Khan CPA
Chief Legal OfficerMs. Shelby Walker J.D.